Spots Global Cancer Trial Database for Preoperative Preradiotherapy TTFields

Study Description

Brief Summary: PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. After the study patients will follow their standard treatment pathway.

Detailed Description: Glioblastoma is the most common primary malignant brain tumour in adults. Its outcomes are poor due to local disease progression in most patients. Current treatment includes surgery followed by chemotherapy and radiotherapy 4-6 weeks after surgery. In this time interval, some tumour cells do not receive any treatment. Furthermore, studies show that around half of all glioblastoma patients experience rapid early progression (REP) i.e. growth of the tumour in the time interval between surgery and postoperative chemotherapy/radiotherapy. REP is associated with a shorter survival and there are currently no effective treatments or preventative measures to address it. Optune is a wearable, portable, FDA-approved glioblastoma (GBM) treatment. It works by creating Tumor Treating Fields (TTFields), which are electric fields that slow down or stop GBM cancer cell division. TTFields is the only treatment modality that contributed to the overall survival in the last decade as shown in one Randomized Controlled Trial. The investigators hypothesize that earlier treatment using Optune before the surgery and between the surgery and postoperative radiotherapy can prevent REP and improve patient outcomes. In this phase 1 trial, PORTRAIT (PreOpeRaTive pRerAdIotherapy Ttfields), the study will test the safety and feasibility of giving Optune before surgery and before post-operative radiotherapy in a maximum of 14 patients. Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. To maximise PORTRAIT's translational and clinically relevant components, a non-experimental arm (Non-EA) of 28 patients will allow comparisons of data collected from PORTRAIT patients with comparable Standard of Care (SoC) treated patients from the same time frame. Participants will be invited to the research study if they are over the age of 35 and have a new radiological diagnosis of glioblastoma. All recruitment and treatment will be conducted at the Christie NHS Foundation Trust and Northern Care Alliance NHS Foundation Trust. The study is funded by a research grant from Novocure.

Keywords

Eligibility

Minimum Age: 35 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial